RESEARCHER PROFILE

Jill Adler‐Moore

← Back to California State Polytechnic University

J

California State Polytechnic University

Antifungal resistance and susceptibilityFungal Infections and StudiesNanoparticle-Based Drug DeliveryAntibiotics Pharmacokinetics and EfficacyFungal and yeast genetics research

Jill Adler‐Moore works in Antifungal resistance and susceptibility, Fungal Infections and Studies, Nanoparticle-Based Drug Delivery, Antibiotics Pharmacokinetics and Efficacy, Fungal and yeast genetics research. Recorded institutional associations include California State Polytechnic University.

64Publications
3,251Citations
26H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis

    2006 · 345 citations
  2. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience

    2002 · 339 citations
  3. Development, Characterization, Efficacy and Mode of Action of Ambisome, A Unilamellar Liposomal Formulation of Amphotericin B

    1993 · 251 citations
  4. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents

    1991 · 203 citations
  5. The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles

    2018 · 170 citations
  6. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines

    2006 · 134 citations
  7. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B

    2019 · 132 citations
  8. Amphotericin B lipid preparations: what are the differences?

    2008 · 128 citations
  9. Functional Interrelationships between Cell Membrane and Cell Wall in Antimicrobial Peptide-Mediated Killing of Staphylococcus aureus

    2005 · 118 citations
  10. Comparison between liposomal formulations of amphotericin B

    2016 · 113 citations
  11. AmBisome targeting to fungal infections.

    1994 · 107 citations
  12. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue.

    1996 · 103 citations
  13. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B

    1991 · 102 citations
  14. In vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry

    2007 · 92 citations
  15. Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B

    2019 · 83 citations
  16. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)

    1991 · 81 citations
  17. Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin

    2005 · 75 citations
  18. Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products

    2007 · 73 citations
  19. Comparative Efficacies, Toxicities, and Tissue Concentrations of Amphotericin B Lipid Formulations in a Murine Pulmonary Aspergillosis Model

    2006 · 72 citations
  20. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B

    2007 · 58 citations
  21. Single-Dose AmBisome (Liposomal Amphotericin B) as Prophylaxis for Murine Systemic Candidiasis and Histoplasmosis

    2000 · 51 citations
  22. Effect of tissue penetration on AmBisome efficacy.

    2003 · 48 citations
  23. Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice

    2014 · 41 citations
  24. Liposomal Amphotericin B and Echinocandins as Monotherapy or Sequential or Concomitant Therapy in Murine Disseminated and Pulmonary Aspergillus fumigatus Infections

    2010 · 30 citations
  25. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis

    2004 · 29 citations
  26. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine

    2011 · 26 citations
  27. Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals

    2019 · 26 citations
  28. Comparison of antifungal treatments for murine fusariosis

    2006 · 25 citations
  29. Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake ofCandida glabrataby murine epidermal Langerhans cells

    1998 · 22 citations
  30. Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens

    2017 · 18 citations
  31. Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B

    2010 · 17 citations
  32. Liposomal gD ectodomain (gD1–306) vaccine protects against HSV2 genital or rectal infection of female and male mice

    2009 · 16 citations
  33. Recombinant Aspergillus fumigatus antigens Asp f 3 and Asp f 9 in liposomal vaccine protect mice against invasive pulmonary aspergillosis

    2022 · 16 citations
  34. Differences in Efficacy and Cytokine Profiles following Echinocandin or Liposomal Amphotericin B Monotherapy or Combination Therapy for Murine Pulmonary or Systemic Aspergillus flavus Infections

    2011 · 15 citations
  35. Effect of testosterone and estrogen supplementation on the resistance to systemic Candida albicans infection in mice

    2020 · 14 citations
  36. Effect of Delta-9-Tetrahydrocannabinol on Mouse Resistance to Systemic Candida albicans Infection

    2014 · 12 citations
  37. Monomeric M2e antigen in VesiVax®liposomes stimulates protection against type a strains of influenza comparable to liposomes with multimeric forms of M2e

    2017 · 11 citations
  38. Unilamellar liposomes for anticancer and antifungal therapy

    1998 · 10 citations
  39. Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections

    2019 · 10 citations
  40. AmBisome®: Long Circulating Liposomal Formulation of Amphotericin B

    1998 · 10 citations
  41. Stability and mode of action of AmBisome® (liposomal amphotericin B)

    1994 · 8 citations
  42. The adjuvant effects of mycoviral dsRNA and polyinosinic:polycytidylic acid on the murine immune response

    1985 · 5 citations
  43. Subcellular particles in pathogenic fungi.

    1985 · 4 citations
  44. Novel Drug Delivery Systems for Antifungal Agents

    2004 · 4 citations
  45. Case Study

    2005 · 3 citations
  46. Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B

    2009 · 1 citations
  47. Comparative in vivo and in vitro distribution of DaunoXome and daunorubicin in P1798 lymphosarcoma cells

    1994 · 0 citations
  48. 1639. Efficacy of Voriconazole Prophylaxis Followed by Therapeutic Liposomal Amphotericin B for the Treatment of Murine Pulmonary Aspergillosis Caused by Azole-Resistant Aspergillus fumigatus Strains

    2018 · 0 citations
  49. 626. An Inexpensive Quantitative Method for Testing Anti-Fungal Drug Activity Using the Invertebrate Caenorhabditis elegans

    2018 · 0 citations
  50. 1554. Nebulized Liposomal Amphotericin B for Treatment of Murine Pulmonary Mucormycosis

    2019 · 0 citations

← Return to the university profile